long intergenic non-protein coding RNA 1106Genealiases: []
Q-omics provides the consensus-scored LINC01106 profile across patient tissues and cancer cell-line models. LINC01106 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC01106 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LINC01106 RNA expression shows 17,886 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, HNSC, and UVM as cancer lineages where LINC01106 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01106 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01106 survival associations across molecular data types. LINC01106 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01106 RNA expression–survival associations across cancer types. High LINC01106 expression shows unfavorable associations in HNSC, KIRP, LAML and LIHC, but favorable associations in BLCA and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC01106 RNA expression.
This table summarizes LINC01106 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01106. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01106 shows lower tumor expression in KIRC, KICH, THCA and BRCA and higher tumor expression in HNSC and STAD. The HNSC box plot shows higher LINC01106 RNA expression in tumor versus normal tissue (log2 FC = +0.369, t-test p < 0.001).
This table shows molecular features associated with LINC01106 in patient tissues and cancer cell lines. In patient samples, LINC01106 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01106 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE.
